Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known ... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and related liver conditions. Its lead product, Rezdiffra (resmetirom), is a liver-directed thyroid hormone receptor beta agonist approved for treating adults with MASH and moderate to advanced liver fibrosis, marking it as the first FDA-approved therapy in this category. The company has also expanded its pipeline through a global licensing agreement for ervogastat, an oral DGAT-2 inhibitor in Phase 2 development, to complement its MASH treatment offerings. Madrigal Pharmaceuticals, Inc. targets the growing demand in the metabolic liver disease market, where it plays a pioneering role with rapid commercialization efforts, including approvals in the United States and Europe. Headquartered in West Conshohocken, Pennsylvania, and founded in 2000, the company concentrates on addressing unmet needs in cardiovascular, metabolic, and liver diseases through targeted oral therapies.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Madrigal Pharmaceuticals is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Madrigal Pharmaceuticals is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Madrigal Pharmaceuticals's data?

Start your 30-day free trial to request a data review for Madrigal Pharmaceuticals.

Start Free Trial

Legal Center Contact Us

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is not subject to EU Taxonomy reporting

Account Restricted